Program
PKC-beta Inhibitor MS-553
Also written as “MS-553”, “MS-553, DS1” and “MS-553, DS2”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Macular Edema · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MingSight Pharmaceuticals | 31 open or running | phase 2since Mar 24, 2018 | Mar 24, 2018 | Sep 2028phase 2 · NCT06979076 |
| Shenzhen MingSight Relin Pharmaceuticals | 21 open or running | phase 2since Feb 18, 2022 | Dec 3, 2019 | none ahead |
| MingSight Pharmaceuticals Pty | 10 open or running | phase 1since Mar 25, 2015 | Mar 25, 2015 | none ahead |
Also a collaborator on its studies: Fountain Medical Development.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2015First study: phase 1 study in Safety and PK in Healthy VolunteersNew to MingSight Pharmaceuticals PtyMingSight Pharmaceuticals Pty · NCT02406989 · 32 enrolled · Australia
- Mar 24, 2018MingSight Pharmaceuticals’ first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to MingSight PharmaceuticalsMingSight Pharmaceuticals · NCT03492125 · 60 enrolled · United States
- Dec 3, 2019Shenzhen MingSight Relin Pharmaceuticals’ first study: phase 1 study in Macular EdemaNew to Shenzhen MingSight Relin PharmaceuticalsShenzhen MingSight Relin Pharmaceuticals · NCT04187443 · 45 planned · China
- Feb 18, 2022Phase 2 study in Leukemia, LymphoidShenzhen MingSight Relin Pharmaceuticals · NCT05272813 · 13 enrolled · China
- Jan 11, 2023Phase 2 study in RecurrenceMingSight Pharmaceuticals · NCT05720052 · 8 enrolled · China
- May 2, 2025Phase 2 study in Leukemia, B-CellMingSight Pharmaceuticals · NCT06979076 · 12 planned
Ahead
- Sep 2028Primary completion: phase 2 study in Leukemia, B-CellMingSight Pharmaceuticals · NCT06979076
TargetBeta
“An orally available inhibitor of the beta-isoform of protein kinase C (PKC), ”NCIt, by rule
Other programs on PRRT2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| darovasertibrule | ideaya-biosciences | phase 3 | 6 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06979076Leukemia, B-Cell | 2 | Not yet recruiting | MingSight Pharmaceuticals | Sep 2028 | 12 |
| NCT05720052Recurrence · China | 2 | Terminated | MingSight Pharmaceuticals | Nov 28, 2023 | 8 |
| NCT05272813Leukemia, Lymphoid · China | 2 | Terminated | Shenzhen MingSight Relin Pharmaceuticals | Nov 28, 2023 | 13 |
| NCT04187443Macular Edema · China | 1 | Recruiting | Shenzhen MingSight Relin Pharmaceuticals | Oct 30, 2026 | 45 |
| NCT03492125Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | MingSight Pharmaceuticals | Nov 28, 2023 | 60 |
| NCT02406989Safety and PK in Healthy Volunteers · Australia | 1 | Completed | MingSight Pharmaceuticals Pty | Aug 2015 | 32 |
How it is read
Names in the registry
- “MS-553”, 6 entries
- “MS-553, DS1”, 1 entry
- “MS-553, DS2”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 3 studies
- Macular Edema, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.